Golimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TNFα |
| Clinical data | |
| Trade names | Simponi |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610010 |
| License data | |
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.226.360 |
| Chemical and physical data | |
| Formula | C6530H10068N1752O2026S44 |
| Molar mass | 147 kDa g·mol−1 |
  (what is this?) (verify) | |
Golimumab (CNTO 148)[2] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[3] and hence is a TNF inhibitor.
Golimumab was developed by Centocor and is approved in Canada[4] and the United States[5] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[6] Golimumab has been approved in 2013 for use in adults with moderately to severely active Crohn's Disease or Ulcerative Colitis.
In the same year, Johnson & Johnson, the parent company of Centocor, also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[7] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[8][9] [10]
Efficacy
Large, randomized, double-blind trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[11]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Mazumdar, Sohini (2009). "Golimumab". mAbs. 1 (5): 422–431. doi:10.4161/mabs.1.5.9286.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab, American Medical Association.
- ^ "Health Canada Approves Simponi (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis". Apr 2009
- ^ FDA Approves Simponi
- ^ "FDA clears potential blockbuster arthritis drug". North County Times. Lee Enterprises. Associated Press. 24 April 2009. Retrieved 23 October 2010.
- ^ Johnson & Johnson Reports 2008 First-Quarter Results
- ^ FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab
- ^ [1] Merck sees fast ruling in J&J Remicade arbitration
- ^ "Simponi European Public Assessment Report". European Medicines Agency. Retrieved 2009-11-15.
- ^ Oldfield V, Plosker GL.[2].Biodrugs 2009;23(2):125-135. doi:10.2165/00063030-200923020-00005.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |